Spinogenix is using small molecule drugs to regenerate synapses in patients with ALS, Alzheimer's disease, schizophrenia, ...

In the second article in a series on the leadership benefits of putting employees first, Christine Miller, president and CEO ...

Part one of a two-part series that identifies current uses of AI in drug discovery and development and assesses whether AI ...

In the rapidly evolving world of life sciences, companies are constantly seeking ways to optimize their business structures to better navigate the complex landscape of drug development and financing.

As professionals within the life sciences industry, a new era is upon us, marked by the pursuit of efficiency. In part this has been driven by legislative measures such as the Inflation Reduction Act ...

What do Annovis Bio’s buntanetap, Pfizer’s Viagra, and Lilly’s GLP-1 drug Trulicity have in common? They could all end up being used together in combination as a new treatment focused on improving ...

Then: In a 2021 “Companies To Watch” article written by Wayne Koberstein, Carisma Therapeutics CEO Steven Kelly spoke about his three-pronged mandate to fund the (then) privately held company, build a ...

Optimizing biomanufacturing is particularly challenging because of variability and complexity associated with the sharing of finite and interdependent resources. Traditional approaches, like polling ...

Inozyme's CEO and chairman Douglas Treco shares his thoughts about the rousing success of the Orphan Drug Act, but cautions rare disease drug developers against sky high and inaccessible drug pricing ...